KNSA

Kiniksa Pharmaceuticals Ltd

KNSA, USA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

https://www.kiniksa.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KNSA
stock
KNSA

How KNSA stock reacts to global recession fears - Breakout Watch & Long-Term Growth Plans Улправда

Read more →
KNSA
stock
KNSA

Will KNSA stock remain a Wall Street favorite - 2025 Technical Overview & Stepwise Entry and Exit Trade Signals Улправда

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$54

Analyst Picks

Strong Buy

4

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

94.49

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

6.04

Low 1

High 3

Return on Equity (ROE)

-

Very Low

3.44 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

2.59 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

18.25 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.33

Low 1

High 0.3

Investors

* Institutions hold a combined 43.95% of the total shares of Kiniksa Pharmaceuticals Ltd

1.

Rubric Capital Management LP

(5.2758%)

since

2025/06/30

2.

Vanguard Group Inc

(4.2257%)

since

2025/06/30

3.

Baker Bros Advisors LP

(3.8116%)

since

2025/06/30

4.

TANG CAPITAL MANAGEMENT LLC

(3.1422%)

since

2025/06/30

5.

Fairmount Funds Management LLC

(2.3922%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(1.6084%)

since

2025/07/31

7.

BRAIDWELL LP

(1.4878%)

since

2025/06/30

8.

Morgan Stanley - Brokerage Accounts

(1.4388%)

since

2025/06/30

9.

Millennium Management LLC

(1.3763%)

since

2025/06/30

10.

Pictet Asset Manangement SA

(1.3286%)

since

2025/06/30

11.

Vanguard Small Cap Index

(1.2476%)

since

2025/07/31

12.

Qube Research & Technologies

(1.1987%)

since

2025/06/30

13.

Point72 Asset Management, L.P.

(1.145%)

since

2025/06/30

14.

FMR Inc

(1.0888%)

since

2025/06/30

15.

D. E. Shaw & Co LP

(1.0678%)

since

2025/06/30

16.

Arrowstreet Capital Limited Partnership

(0.9924%)

since

2025/06/30

17.

BlackRock Inc

(0.9485%)

since

2025/06/30

18.

Cubist Systematic Strategies, LLC

(0.8872%)

since

2025/06/30

19.

Dimensional Fund Advisors, Inc.

(0.8749%)

since

2025/06/30

20.

Driehaus Capital Management LLC

(0.8744%)

since

2025/06/30

21.

Rice Hall James & Associates, LLC

(0.8612%)

since

2025/06/30

22.

Connor Clark & Lunn Inv Mgmt Ltd

(0.8416%)

since

2025/06/30

23.

Pictet-Biotech P USD

(0.73%)

since

2025/05/31

24.

Vanguard Small Cap Growth Index Inv

(0.7078%)

since

2025/07/31

25.

Fidelity Small Cap Growth

(0.6616%)

since

2025/06/30

26.

Pictet-Global Megatrend Sel I USD

(0.5638%)

since

2025/05/31

27.

Oberweis Micro-Cap

(0.4118%)

since

2025/06/30

28.

Oberweis Micro-Cap Growth

(0.4118%)

since

2025/06/30

29.

Heptagon Driehaus US Micro Cap Eq C$ Acc

(0.3624%)

since

2025/07/31

30.

Fidelity Small Cap Growth K6

(0.3032%)

since

2025/06/30

31.

Xtrackers MSCI World Swap ETF 1C

(0.2266%)

since

2025/07/31

32.

Xtrackers S&P 500 Swap ETF 1C

(0.1893%)

since

2025/07/31

33.

Peregrine Capital Mgt Sm-Cap Growth

(0.1758%)

since

2025/06/30

34.

Allspring Small Company Gr

(0.1668%)

since

2025/07/31

35.

Allspring Small Company Growth A

(0.1668%)

since

2025/07/31

36.

Vanguard Strategic Equity Inv

(0.162%)

since

2025/06/30

37.

DFA US Small Cap I

(0.1575%)

since

2025/07/31

38.

Scout Small Cap Equity

(0.1501%)

since

2024/12/31

39.

Vanguard Explorer Inv

(0.1494%)

since

2025/06/30

40.

Driehaus Micro Cap Growth USD

(0.1425%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

0.23

EPS Estimate

0.3139

EPS Difference

-0.0839

Surprise Percent

-26.7283%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(7.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.